Inhibition of soluble epoxide hydrolase does not protect against endotoxin-mediated hepatic inflammation

Journal of Pharmacology and Experimental Therapeutics

Volumn 327, Issue 3, 2008, Pages 707-715

  Fife, Kimberly L ^a   Liu, YingMei ^a   Schmelzer, Kara R ^b   Tsai, Hsing Ju ^b   Kim, In Hae ^b   Morisseau, Christophe ^b   Hammock, Bruce D ^b   Kroetz, Deanna L ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 ADAMANTAN 1 YL 3 [5 [2 (2 ETHOXYETHOXY)ETHOXY]PENTYL]UREA; 12 (3 ADAMANTAN 1 YLUREIDO)DODECANOIC ACID; 12 (3 ADAMANTAN 1 YLUREIDO)DODECANOIC ACID POLYETHYLENE GLYCOL ESTER; 2 HYDROXYPROPYL BETA CYCLODEXTRIN; ARACHIDONIC ACID; ARACHIDONIC ACID DERIVATIVE; CYTOCHROME P450; DIHYDROEICOSATRIENOIC ACID; ENDOTOXIN; ENZYME INHIBITOR; EPOXIDE HYDROLASE; EPOXYICOSATRIENOIC ACID; ICOSANOID; LIPOPOLYSACCHARIDE; MESSENGER RNA; POLYETHYLENE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CATALYST; CHEMICAL REACTION; CONTINUOUS INFUSION; CONTROLLED STUDY; DOWN REGULATION; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME MECHANISM; EPOXYGENATION; GENE DISRUPTION; GENE EXPRESSION REGULATION; HEPATITIS; ICOSANOID METABOLISM; IN VIVO STUDY; INFLAMMATION; KNOCKOUT MOUSE; MALE; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION;

ADAMANTANE; ANIMALS; DOWN-REGULATION; EICOSANOIDS; ENDOTOXINS; ENZYME INHIBITORS; EPOXIDE HYDROLASES; HEPATITIS, ANIMAL; HEPATITIS, TOXIC; INFLAMMATION MEDIATORS; LAURIC ACIDS; MICE; NEUTROPHIL INFILTRATION;

EID: 57349120615     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.108.142398     Document Type: Article

References (39)

1. Ai D, Fu Y, Guo D, Tanaka H, Wang N, Tang C, Hammock BD, Shyy JY, and Zhu Y (2007) Angiotensin II up-regulates soluble epoxide hydrolase in vascular endothelium in vitro and in vivo. Proc Natl Acad Sci U S A 104:9018-9023.
2. Borhan B, Mebrahtu T, Nazarian S, Kurth MJ, and Hammock BD (1995) Improved radiolabeled substrates for soluble epoxide hydrolase. Anal Biochem 231:188-200.
3. Campbell WB and Falck JR (2007) Arachidonic acid metabolites as endothelium-derived hyperpolarizing factors. Hypertension 49:590-596.
4. Chacos N, Capdevila J, Falck JR, Manna S, Martin-Wixtrom C, Gill SS, Hammock BD, and Estabrook RW (1983) The reaction of arachidonic acid epoxides (epoxyeicosatrienoic acids) with a cytosolic epoxide hydrolase. Arch Biochem Biophys 223:639-648.
5. 2+-dependent translocation domain with homology to PKC and GAP. Cell 65:1043-1051.
6. Davis BB, Thompson DA, Howard LL, Morisseau C, Hammock BD, and Weiss RH (2002) Inhibitors of soluble epoxide hydrolase attenuate vascular smooth muscle cell proliferation. Proc Natl Acad Sci U S A 99:2222-2227.
7. Dorrance AM, Rupp N, Pollock DM, Newman JW, Hammock BD, and Imig JD (2005) An epoxide hydrolase inhibitor, 12-(3-adamantan-1-yl-ureido)dodecanoic acid (AUDA), reduces ischemic cerebral infarct size in stroke-prone spontaneously hypertensive rats. J Cardiovasc Pharmacol 46:842-848.
8. Fang X, Weintraub NL, and Spector AA (2003) Differences in positional esterification of 14,15-epoxyeicosatrienoic acid in phosphatidylcholine of porcine coronary artery endothelial and smooth muscle cells. Prostaglandins Other Lipid Mediat 71:33-42.
9. Fleming I, Michaelis UR, Bredenkötter D, Fisslthaler B, Dehghani F, Brandes RP, and Busse R (2001) Endothelium-derived hyperpolarizing factor synthase (cytochrome P450 2C9) is a functionally significant source of reactive oxygen species in coronary arteries. Circ Res 88:44-51.
10. Hutchens MP, Nakano T, Dunlap J, Traystman RJ, Hurn PD, and Alkayed NJ (2008) Soluble epoxide hydrolase gene deletion reduces survival after cardiac arrest and cardiopulmonary resuscitation. Resuscitation 76:89-94.
11. Hwang SH, Tsai HJ, Liu JY, Morisseau C, and Hammock BD (2007) Orally bioavailable potent soluble epoxide hydrolase inhibitors. J Med Chem 50:3825-3840.
12. Imig JD, Zhao X, Capdevila JH, Morisseau C, and Hammock BD (2002) Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension. Hypertension 39:690-694.
13. Imig JD, Zhao X, Zaharis CZ, Olearczyk JJ, Pollock DM, Newman JW, Kim IH, Watanabe T, and Hammock BD (2005) An orally active epoxide hydrolase inhibitor lowers blood pressure and provides renal protection in salt-sensitive hypertension. Hypertension 46:975-981.
14. Jung O, Brandes RP, Kim IH, Schweda F, Schmidt R, Hammock BD, Busse R, and Fleming I (2005) Soluble epoxide hydrolase is a main effector of angiotensin II-induced hypertension. Hypertension 45:759-765.
15. Karara A, Wei S, Spady D, Swift L, Capdevila JH, and Falck JR (1992) Arachidonic acid epoxygenase: structural characterization and quantification of epoxyeicosatrienoates in plasma. Biochem Biophys Res Commun 182:1320-1325.
16. Kim IH, Nishi K, Tsai HJ, Bradford T, Koda Y, Watanabe T, Morisseau C, Blanchfield J, Toth I, and Hammock BD (2007a) Design of bioavailable derivatives of 12-(3-adamantan-1-yl-ureido)dodecanoic acid, a potent inhibitor of the soluble epoxide hydrolase. Bioorg Med Chem 15:312-323.
17. Kim IH, Tsai HJ, Nishi K, Kasagami T, Morisseau C, and Hammock BD (2007b) 1,3-Disubstituted ureas functionalized with ether groups are potent inhibitors of the soluble epoxide hydrolase with improved pharmacokinetic properties. J Med Chem 50:5217-5226.
18. Liu Y, Zhang Y, Schmelzer K, Lee TS, Fang X, Zhu Y, Spector AA, Gill S, Morisseau C, Hammock BD, et al. (2005) The antiinflammatory effect of laminar flow: the role of PPARγ, epoxyeicosatrienoic acids, and soluble epoxide hydrolase. Proc Natl Acad Sci U S A 102:16747-16752.
19. Loch D, Hoey A, Morisseau C, Hammock BO, and Brown L (2007) Prevention of hypertension in DOCA-salt rats by an inhibitor of soluble epoxide hydrolase. Cell Biochem Biophys 47:87-98.
20. Luria A, Weldon SM, Kabcenell AK, Ingraham RH, Matera D, Jiang H, Gill R, Morisseau C, Newman JW, and Hammock BD (2007) Compensatory mechanism for homeostatic blood pressure regulation in Ephx2 gene-disrupted mice. J Biol Chem 282:2891-2898.
21. Mathison JC and Ulevitch RJ (1979) The clearance, tissue distribution, and cellular localization of intravenously injected lipopolysaccharide in rabbits. J Immunol 123:2133-2143.
22. Morisseau C, Goodrow MH, Newman JW, Wheelock CE, Dowdy DL, and Hammock BD (2002) Structural refinement of inhibitors of urea-based soluble epoxide hydrolases. Biochem Pharmacol 63:1599-1608.
23. Newman JW, Watanabe T, and Hammock BD (2002) The simultaneous quantification of cytochrome P450 dependent linoleate and arachidonate metabolites in urine by HPLC-MS/MS. J Lipid Res 43:1563-1578.
24. Node K, Huo Y, Ruan X, Yang B, Spiecker M, Ley K, Zeldin DC, and Liao JK (1999) Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science 285:1276-1279.
25. Pokreisz P, Fleming I, Kiss L, Barbosa-Sicard E, Fisslthaler B, Falck JR, Hammock BD, Kim IH, Szelid Z, Vermeersch P, et al. (2006) Cytochrome P450 epoxygenase gene function in hypoxic pulmonary vasoconstriction and pulmonary vascular remodeling. Hypertension 47:762-770.
26. 2 in human leukocytes by lipopolysaccharide. Eur J Biochem 223:743-749.
27. Schmelzer KR, Kubala L, Newman JW, Kim IH, Eiserich JP, and Hammock BD (2005) Soluble epoxide hydrolase is a therapeutic target for acute inflammation. Proc Natl Acad Sci U S A 102:9772-9777.
28. Seubert JM, Sinal CJ, Graves J, DeGraff LM, Bradbury JA, Lee CR, Goralski K, Carey MA, Luria A, Newman JW, et al. (2006) Role of soluble epoxide hydrolase in postischemic recovery of heart contractile function. Circ Res 99:442-450.
29. Seubert JM, Zeldin DC, Nithipatikom K, and Gross GJ (2007) Role of epoxyeicosatrienoic acids in protecting the myocardium following ischemia/reperfusion injury. Prostaglandins Other Lipid Mediat 82:50-59.
30. Sinal CJ, Miyata M, Tohkin M, Nagata K, Bend JR, and Gonzalez FJ (2000) Targeted disruption of soluble epoxide hydrolase reveals a role in blood pressure regulation. J Biol Chem 275:40504-40510.
31. Smith KR, Pinkerton KE, Watanabe T, Pedersen TL, Ma SJ, and Hammock BD (2005) Attenuation of tobacco smoke-induced lung inflammation by treatment with a soluble epoxide hydrolase inhibitor. Proc Natl Acad Sci U S A 102:2186-2191.
32. Spector AA and Norris AW (2007) Action of epoxyeicosatrienoic acids on cellular function. Am J Physiol Cell Physiol 292:C996-C1012.
33. Van Amersfoort ES, Van Berkel TJ, and Kuiper J (2003) Receptors, mediators, and mechanisms involved in bacterial sepsis and septic shock. Clin Microbiol Rev 16:379-414.
34. Xie GQ, Jiang JX, Chen YH, Liu DW, Zhu PF, and Wang ZG (2002) Induction of acute hepatic injury by endotoxin in mice. Hepatobiliary Pancreat Dis Int 1:558-564.
35. Xu D, Li N, He Y, Timofeyev V, Lu L, Tsai HJ, Kim IH, Tuteja D, Mateo RK, Singapuri A, et al. (2006) Prevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitors. Proc Natl Acad Sci U S A 103:18733-18738.
36. Yu Z, Xu F, Huse LM, Morisseau C, Draper AJ, Newman JW, Parker C, Graham L, Engler MM, Hammock BD, et al. (2000) Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids. Circ Res 87:992-998.
37. Zeldin DC, Kobayashi J, Falck JR, Winder BS, Hammock BD, Snapper JR, and Capdevila JH (1993) Regio- and enantiofacial selectivity of epoxyeicosatrienoic acid hydration by cytosolic epoxide hydrolase. J Biol Chem 268:6402-6407.
38. Zhang W, Koerner IP, Noppens R, Grafe M, Tsai HJ, Morisseau C, Luria A, Hammock BD, Falck JR, and Alkayed NJ (2007) Soluble epoxide hydrolase: a novel therapeutic target in stroke. J Cereb Blood Flow Metab 27:1931-1940.
39. Zhao X, Yamamoto T, Newman JW, Kim IH, Watanabe T, Hammock BD, Stewart J, Pollock JS, Pollock DM, and Imig JD (2004) Soluble epoxide hydrolase inhibition protects the kidney from hypertension-induced damage. J Am Soc Nephrol 15:1244-1253.